Innovation

Limited to unlimited

Innovation

Innovation is one of the fundamental values in our business. Field of medical and pharmaceutical is full of next generation where innovation is the key to be in this game. At CHAEUM PHARMA, we push the limits of knowledge to discover the tradition to be new approach,
limited to unlimited.

Innvation

Intensive R&D

Our creativity originated from our stubbornness
to sustain the pure sources at high standard.
Every single material is rigidly selected by years of studies and scientific discover under strict disciplines.

With the acceleration of new technologies, CHAEUM PHARMA is increasing its capacity for innovation to create and develop ever more personalized and inclusive products, services and natural experiences.

Innvation

Manufacturing

Excellence is our guide.

We are in a constant quest to offer the best. All our manufacturing facilities are under the highly selected standard to maintain the quality that has been proven by years. Consistency is a key to carry out the best quality in global market.

Four manufacturing facilities are environmentally controlled in 3 different continents, under 42 qualification including ISO, GMP, KGMP, FDA, CFDA, ANVISA, MDSAP, CE(EC), etc, which applied to each facility under strict condition to fulfill human-environmental familiar system.

Safety and quality record.

In accordance with medical standard, all product under UDI&EAN system are traceable which allow us carry out the market surveillance and keep the safety-quality measure. Safety and quality are essential pillars of our business conduct, and key to our long-trusted relationships with consumers, patients and healthcare professionals.

Our quality and manufacturing processes adhere to a number of local and global laws and regulations.

Project California

This is new concept of agile factory to reinforce abandoned factory since 1980s as a part of ‘encouraging employment’ and ‘renovation of outskirt of city of beauty.’

New ‘Project California’ is strategic outpoint for US market by 3rd quarter of 2026. Invested and governed by CHAEUM GROUP INC. managed by CHAEUM PHARMA.